Compare AIR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIR | RCUS |
|---|---|---|
| Founded | 1951 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.2B |
| IPO Year | 1994 | 2018 |
| Metric | AIR | RCUS |
|---|---|---|
| Price | $97.22 | $17.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | ★ $154.50 | $41.00 |
| AVG Volume (30 Days) | 601.8K | ★ 2.0M |
| Earning Date | 09-28-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1288.57 | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $11.56 | N/A |
| Revenue Next Year | $6.80 | N/A |
| P/E Ratio | $95.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.10 | $17.43 |
| 52 Week High | $154.00 | $31.74 |
| Indicator | AIR | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 33.88 | 25.73 |
| Support Level | N/A | N/A |
| Resistance Level | $121.24 | $24.38 |
| Average True Range (ATR) | 3.40 | 1.67 |
| MACD | 0.65 | -0.48 |
| Stochastic Oscillator | 51.67 | 3.77 |
AAR Corp offers a broad line of products and services to commercial and government aerospace customers and operates internationally. It is a diversified provider of services and products to the commercial aviation and government and defense markets, serving aircraft fleet operators, original equipment manufacturers, independent service providers, and domestic and foreign military customers. It operates through the Parts Supply, Repair, Engineering and Software, Government Solutions, and Legacy Commercial Programs segments. The Parts Supply segment mainly consists of new parts distribution and sales of used serviceable material, including aircraft, engine, and airframe parts and components (USM), and generates the maximum revenue. It generates the maximum revenue from North America.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.